Instylla Inc.February 3, 2026Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System
EyeCool TherapeuticsMay 7, 2025EyeCool Therapeutics Announces Promising Results from Double-Masked Randomized Controlled Trial in Chronic Ocular Surface Pain (COSP)
